Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
此前报道，武田宣布美国食品药品管理局批准ENTYVIO皮下给药用于中度至重度活性克罗恩病的维持治疗
ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
ENTYVIO现已在美国提供静脉和皮下给药两种形式，用于中度至重度活动性溃疡性结肠炎或克罗恩氏病的成年人的维持性治疗